The medical treatment of overactive bladder;Le traitement médical de l'hyperactivité vésicale

Neurochirurgie

Volumn 49, Issue 2-3 II, 2003, Pages 369-376

  Beneton, C ^a   De Parisot, O ^a  

^a Centre Medical Germaine Revel   (France)

Author keywords

Anticholinergic drugs; Uninhibited contractions; Vanilloid substances, botulinum toxin, intermittent catheterization

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DESMOPRESSIN; DIURETIC AGENT; FLAVOXATE; IMIPRAMINE; LIDOCAINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; POTASSIUM CHANNEL STIMULATING AGENT; PROPANTHELINE BROMIDE; PROPIVERINE; RESINIFERATOXIN; SPASMOLYTIC AGENT; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE; VANILLOID RECEPTOR;

ANTICHOLINERGIC EFFECT; BLADDER CATHETERIZATION; BLADDER COMPLIANCE; CARDIOVASCULAR DISEASE; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CYSTOMETRY; DECISION MAKING; DETRUSOR MUSCLE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPONATREMIA; HYPOTENSION; INJECTION; LOCAL THERAPY; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MICTURITION REFLEX; NERVE FIBER; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROSURGERY; NOCICEPTION; NONHUMAN; OVERACTIVE BLADDER; PAIN; PARASYMPATHETIC INNERVATION; PATIENT EDUCATION; QUALITY OF LIFE; SENSORY NERVE; SIDE EFFECT; SYMPTOM; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; URINARY DYSFUNCTION; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; URODYNAMICS; UROLOGIC SURGERY;

CLINICAL TRIALS; HUMANS; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; URINARY BLADDER DISEASES; URINARY CATHETERIZATION;

EID: 0038404929     PISSN: 00283770     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. ABRAMS P, FREEMAN R, ANDERSTROM C. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81: 801-810.
2. AMARENCO G, ADBA MA, KERDRAON J, DENYS P, PERRIGOT M. Apport des instillations intravésicales d'oxybutynine dans le traitement des vessies hyperactives rebelles. Ann Readapt Med Phys 1993;36:285-288.
3. AMARENCO G, BOSC S, BOITEAU F, PERRIGOT M. Étude de l'efficacité des traitements des troubles vésicosphinctériens de la sclérosc en plaques. À propos de 150 cas. Ann Readapt Med Phys 1996; 39: 179-182.
4. ANDERSSON KE. Treatment of overactive bladder: other drug mechanisms. Urology 2000; 55: 51-59.
5. ANDERSSON KE, Chapple CR. Oxubutynin and the overactive bladder. World J Urol 2001; 19: 319-323.
6. AVELINO A, CRUZ F, COIMBRA A. Lidocaine prevents noxious excitation of bladder afferents induced by intravesical capsaicin without interfering with the ensuing sensory desensitization: an experimental study in the rat. J Urol 1998; 159: 567-570.
7. BENETON C, MERTENS P, LERICHE A, SINDOU M. The spastic bladder and its treatment. In: Sindou M, Abbott R, Keravel Y, eds. Neursurgery for spaticity: a multidisciplinary approach. Wien: Springer-Verlag, 1991: 193-199.
8. BLAIVAS JG, LABIB KB, MICHALIK J, ZAYED AAH. Cystometric response to propantheline in detrusor hyperreflexia: therapeutic implications. J Urol 1980; 124: 259-262.
9. BULMER P, ABRAMS P. The overactive bladder. Rev Contemp Pharmacother 2000; 11: 1-11.
10. CHANCELLOR MB, DE GROAT WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 1999; 162: 3-11.
11. CHAPPLE CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55: 33-46.
12. CRUZ F, GUIMARAES M, SILVA C, RIO ME, COIMBRA A, REIS M. Desensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. J Urol 1997; 157: 585-589.
13. CRUZ F, GUIMARAES M, SILVA C, REIS M. Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet 1997; 350: 640-641.
14. DASGUPTA P, CHANDIRAMANI V, PARKINSON MC, BECKETT A, FOWLER CJ. Treating the human bladder with capsaicin: is it safe? Eur Urol 1998; 33: 28-31.
15. DE GROAT WC, KAWATATNI T, HISAMITSU T. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 1990; 30: 71-78.
16. DE RIDDER D, CHANDIRAMANI V, DASGUPTA P, VAN HOPPEL H, BAERT L, FOWLER CJ. Intravesical capsaicin as a treatment for refracctory detrusor hyperreflexia: a dual center study with long term follow-up. J Urol 1997; 158: 2087-2092.
17. DE SÈZE M, WIART L, FERRIÈRE JM, DE SÈZE MP, JOSEPH PA, BARAT M. Intravesical instillation of capsaicin in urology: a review of the litterature. Eur Urol 1999; 36: 267-277.
18. DE SÈZE M, WIART L, DE SÈZE MP, JOSEPH PA, BROCHET B, FERRIÈRE JM, et al. Capsaïcine intravésicale et hyperreflexie du detrusor. Expérience de 100 instillations sur une période de 5 ans. Ann Readapt Med Phys 2001: 44: 1-11.
19. DE SÈZE M, WIART L, SOYEUR L, JOSEPH PA. Les nouveaux traitements médicaux de l'hyperactivité vésicale neurogène. In: Amarenco G, Prévinaire JG, eds. Troubles vésico-sphinctériens. Actualités en 2002. Paris: Springer-Verlag, 2002: 75-95.
20. DENYS P, CHARTIER-KASTLER E. Les autres traitements de l'hyperactivité de la vessie. In: Amarenco G, Serment G, eds. L'hyperactivité vésicale. Paris: Elsevier, 1998: 167-183.
21. DRUTZ HP, APPELL RA, GLEASON D, KLINBERG I, RADOMSKY S. Long term treatment with tolterodine in patients with overactive bladder. Neurourol Urodyn 1998; 17: 317.
22. FOWLER CJ, BECK RO, GERRARD S, BETTS CD, FOWLER CG. Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 1994; 57: 169-173.
23. FOWLER CJ. Intravesical treatment of overactive bladder. Urology 2000; 55: 60-64.
24. HAAB F. Traitement médical per os de l'instabilité vésicale. In: Amarenco G, Serment G, eds. L'hyperactivité vésicale. Paris: Elsevier, 1998: 159-165.
25. KasaBian NG, BAUER SB, DYRO FM, COLODRY AH, MANDELL J, RETIK AB. The prophylactic value of clean intermittent catheterisation and anticholinergic medication in newborns and infants with myelodysplasia at risks of developping urinary tract deterioration. Am J Dis Child 1992; 146: 840-843.
26. LAZZERI M, BENEFORTI P, TURINI D. Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. J Urol 1997; 158: 2093-2096.
27. MADERSBACHER H, STÖHRER M, RICHTER R, BURGDORFER H, HACHEN HH, MURTZ G. Trospium chloride versus oxybutynin: a randomized, double blind, multicenter trial in the treatment of detrusor hyperreflexia. Br J Urol 1995; 75: 452-456.
28. MALONE-LEE J, SHAFFU B, ANAND C, POWELL C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50-year-old or older with overactive bladder: a randomized controlled trial. J Urol 2001; 165: 1452-1456.
29. PERRIGOT M, FUCHS S. Support neurologique de l'hyperactivité vésicale. In: Amarenco G, Serment G, eds. L'hyperactivité vésicale. Paris: Elsevier, 1998: 9-22.
30. REBEYROTTE I, DAVIET JC, SALLE JY, BORIE MJ, MUNOZ M, DUDOGNON P. La desmopressine dans la prise en charge des vessies neurologiques: efficacité et tolérance. Ann Readapt Med Phys 2000; 43: 499-506.
31. ROVNER ES, WEIN AJ. Once-daily, extended release formulations of antimuscarinic agents in the treatement of overactive bladder: a review. Eur Urol 2002; 41: 61-4.
32. SCHULTE-BAUKLOH H, MICHAEL T, SCHOBERT J, STOLZE T, KNISPEL HH. Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 2002; 59: 325-328.
33. SCHURCH B, STOHRER M, KRAMER G, SCHMID M, GAUL G, HAURI D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to treat anti-cholinergic drugs? Preliminary results. J Urol 2000; 164: 692-697.
34. SERELS SR, APPELL RA. Tolterodine: a new antimuscarinic agent for the treatment of the overactive bladder. Drugs evaluation 1999; 17: 1073-1078.
35. UCKERT S, STIEF CG, ODENTHAL KP, TRUSS MC, LIETZ B, JONAS U. Responses of isolated normal human detrusor muscle to various spasmolytic drugs commonly used in the treatment of the overactive bladder. Arzneimittelforschung 2000; 50: 456-460.
36. VAN KERREBROEK PE, AMARENCO G, THOROFF JW, MADERSBACHER H, LOCK MTWT, MESSELINK EJ, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998; 17: 499-512.
37. WEIN AJ. Pharmacologic options for the overactive bladder. Urology 1998; 51: 43-47.
38. WIART L, JOSEPH PA, PETIT H, DOSQUE JP, DE SÈZE M, BROCHET B, et al. The effects of capsaicin in neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results. Spinal Cord 1998; 36: 95-99.